



A



B



Supplementary Figure 1. Patients and samples. **A.** CfDNA concentration was measured in the plasma of patients with hormone receptor-positive HER2-negative (HR+HER2-) and triple-negative breast cancer (TNBC). Blood was collected at pretreatment (T0), 3 weeks after treatment initiation (T1), 12 weeks after treatment initiation between paclitaxel-based treatment and anthracycline regimens (T2), and after neoadjuvant chemotherapy before surgery (T3); **B.** Pie chart showing the number and proportion of patients assigned to each treatment arm. HR+HER2- and TNBC patients were balanced across different arms (Fisher's exact p=0.41)